|
Mutation Information
|
Mutation Site
|
M204I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Genotype/Subtype
|
C |
|
Viral Reference
|
GQ872210
|
|
Relevant Drug
|
tenofovir |
|
Country
|
Japan |
Literature Information
|
PubMed PMID
|
33462964
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2021 |
|
Journal
|
Hepatology research : the official journal of the Japan Society of Hepatology |
|
Title
|
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir. |
|
Author
|
Suzuki F,Sezaki H,Hosaka T,Suzuki Y,Fujiyama S,Kawamura Y,Akuta N,Kobayashi M,Saitoh S,Arase Y,Ikeda K,Kobayashi M,Mineta R,Suzuki Y,Kumada H |
|
Evidence
|
A recent Korean report showed that two patients with viral breakthrough during treatment with TDF-containing regimens were found to carry five reverse transcriptase (rt) mutations ([rt]S106C[C], rtH126Y[Y], rtD134E[E], rtM204I/V, and rtL269I [I]), with the C, Y, E, and I mutations being associated with tenofovir resistance.
|
|
|
HBV Mutation Detail Information